Indica Labs today announces the launch of the High Dimensional Analysis module for the HALO® image analysis platform. This exciting new functionality for customers in the life sciences enables advanced phenotypic characterization and spatial analysis as well as the exploration of highly multiplexed datasets in either brightfield or fluorescence.
Traditional pathology workflows, while effective, have inherent inefficiencies and limitations—especially for high-volume samples like prostate biopsies. Over decades, the promises of digital pathology often failed to deliver significant improvements. However, with the advent of Lumea’s technologies—like the BxBoard® and BxChip®—the field is finally witnessing measurable advances in efficiency, diagnostic accuracy, and patient outcomes.
Join us for this Thought Leaders episode as Prasanth Perugupalli, Chief Product Officer at Pramana, shares his insights on the evolution of computational pathology, the role of AI in unlocking data from whole slide images, and what it takes to drive real-world adoption in labs around the world.
In this episode, Dr. Matthew O. Leavitt takes us through his digital pathology journey and what he’s learned along the way. Dr. Leavitt’s vision has always been to use digital technologies to improve care, especially in remote areas. He shares his experiences implementing digital pathology, the challenges faced, and the realization that standardization of tissue handling (pre-analytics) is crucial for efficient digital pathology workflows.
The United States and Canadian Academy of Pathology (USCAP) Annual Meeting is always a standout—a forum for trading the latest insights, engaging with the Concentriq community, and enjoying time with our team. This year’s event was no exception. Digital pathology and AI took center stage as the focus on precision medicine was stronger than ever. We left [...]
Paige, a leader in next-generation AI technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to Paige PanCancer Detect*, an AI-assisted diagnostic application intended to assist pathologists in the detection of foci that are suspicious for cancer across a wide range of tissue from multiple organs.
Traditionally, pathologists diagnose cancer and rare diseases by looking for abnormalities in tumor tissue and cells under a microscope, however, that is a time-consuming process often prone to errors. With the advent of whole slide imaging, pathologists are slowly migrating to a fully digital workflow. Whole slide imaging is the process of digitization of tissue samples on glass slides using digital whole slide scanners, enabling clinicians in histopathology, immunohistochemistry, and cytology to view, manipulate, interpret and digitally store the digital images, optimizing their workflow. Digitization also allows pathologists to interpret images using computational approaches, with the potential to improve accuracy, reduce inter-observer variability and provide new insights from a patient’s biopsy. Ultimately digital and computational pathology workflows will help clinicians and researchers discover, diagnose and treat diseases like cancer faster.
Diagnexia has announced a partnership with Stratipath AB to bring Stratipath Breast, an AI-based prognostic risk profiling tool, to healthcare providers across the UK and Europe.
Deep Bio, a pioneer in AI-powered digital pathology, will present new research at the American Association for Cancer Research (AACR) Annual Meeting 2025, highlighting the role of artificial intelligence in enhancing biomarker quantification and cancer diagnostics. The company’s findings will be showcased in multiple poster presentations based on deep learning models for PD-L1 and c-MET IHC quantification and frozen-section lymph node diagnosis.
AIVIS, a leading medical AI company specializing in digital pathology, announced that it has received regulatory approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for its latest AI-powered in vitro diagnostic software, Qanti Ki-67 Micro. The newly approved solution enables automated quantification of Ki-67—a key biomarker used to assess tumor cell proliferation—using only microscope-captured images, reducing reliance on capital-intensive digital scanners and offering a more accessible alternative.
